Innovations • Global Impact • In The News • Our People
AAHI Rings in the New Year with Exciting Plans Ahead
We look forward to pursuing clinical development plans for several of our vaccine candidates, including influenza, HIV, and amebiasis, while continuing our innovative development of novel immune-enhancing platforms.
The latest scientific breakthroughs at AAHI.
Adding AAHI's Adjuvant Technology to a Traditional Protein Vaccine Allows for Broad Protection Lasting at Least a Year, Potentially Overcoming a Key Limitation of Current RNA Vaccines
A preclinical study published In Science Translational Medicine compared the effectiveness of a SARS-CoV-2 protein combined with AAHI's 3M-052-SE adjuvant formulation to Moderna s COVID mRNA vaccine in infant monkeys one year after immunization. The vaccine including AAHI's adjuvant formulation provided greater protection against SARS CoV-2 and its variants.
Every Ingredient of a Formulation Matters
AAHI scientists leveraged their deep formulation expertise and discovered that a component of AAHI’s adjuvant formulations has unexpected property of further stimulating and enhancing immune responses in a preclinical study published in Pharmaceutics, highlighting the intricacies of formulation development.
Make your products accessible to those who need them most. Collaborate with AAHI.
Collaboration across communities. Explore AAHI's different areas of impact.
AAHI Presents 2022 Sustainable Development Goals Report
We shared our progress towards our global goals, in alignment with the United Nation's Sustainable Development Goals for 2030, at Global WA's Goalmaker's Annual Conference. The report embodies our commitment to building a world in which every person has access to effective, sustainably manufactured, and thermostable vaccines and immunotherapies that allow them to live a healthy life, free of illness and disease.
Help us make impossible vaccines possible.
IN THE NEWS
By Joanna Owens, PhD
"We focus on the practical and perhaps less glamorous side of vaccine science," Emily Voigt, PhD, Principal Scientist tells Technology Networks. "We realized before the pandemic that while RNA vaccines had significant benefits for pandemic response, significant drawbacks - particularly their complexity of manufacturing and stability - would cause them to be difficult to manufacture and distribute worldwide. So, we focused on developing a simpler, potent, and stable RNA Vaccine technology that we applied to Covid."
Collaboration across communities. Explore our different areas of impact.
Openings and Opportunities
The Associate / Staff Scientist will be responsible for performing assay development, optimizations and
validations, preparation of blood specimens for ex vivo assays under BSL 2 conditions, performing a
variety of immunological assays, and assisting in drafting manuscripts.
The Associate / Staff Scientist will be responsible for managing and executing formulation development
and stability studies, including collecting, analyzing, reviewing, and reporting bulk antigen and drug
product characterization for multiple projects.
The Senior Scientist joining our RNA vaccine team will be responsible for broadening the applications of
AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets.
Learn more about our formulation technology
We partner with biotech leaders to develop vaccines and more.
Synthetic TLR4 ligand in squalene nanoemulsion
Synthetic TLR4 ligand in QS- 21 containing liposome
Synthetic TLR4 ligand in aqueous formulation
Dual agonist containing both TLR4 and TLR7/8 ligands
Synthetic TLR7/8 ligand in
Synthetic TLR7/8 ligand
adsorbed to aluminum
Synthetic TLR7/8 ligand in
Nanostructured lipid carrier
See how our formulations are being used.
Sign up to stay in touch!
Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.